SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Business
Money on the Move: August 18 – 24
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
August 24, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
August 24, 2021
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Soumyabrata Roy/NurPhoto via Getty
Policy
FDA Says “Stop It” to Self-Medicating for COVID-19 with Unapproved Treatments
“You are not a horse. You are not a cow. Seriously, y’all. Stop it.” This is the FDA’s recently tweeted advice to Americans seeking out alternative, unapproved treatments for COVID-19.
August 23, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Although Rare, New Data Suggests Higher Rate of Myocarditis with Moderna Shot
As governments and now even businesses push citizens to get vaccinated against COVID-19, anti-vaxxers are loading up more ammo for their argument with this week’s report.
August 20, 2021
 · 
2 min read
 · 
Kate Goodwin
Employer Resources
As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
August 19, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Money on the Move: August 11 – 17
Here’s the shortlist of which life sciences companies took a dip in the money pool this week.
August 18, 2021
 · 
3 min read
 · 
Kate Goodwin
Fabry disease is caused due to buildup of globotri
Deals
Eight Months After First FDA Approval, Aurinia Picks Up Two More Candidates
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
August 17, 2021
 · 
2 min read
 · 
Kate Goodwin
Can H10N3 Avian Flu strain become the next new pan
Drug Development
Hoping to Change the Game, Bharat’s Intranasal Vaccine Moves Forward
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
August 16, 2021
 · 
2 min read
 · 
Kate Goodwin
Valery Sharifulin\TASS via Getty Images
Deals
Asthma Pharma Board Backs Big Tobacco Bid for $1 Billion Buyout
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.
August 13, 2021
 · 
2 min read
 · 
Kate Goodwin
Alexandria Real Estate Equities, Inc.
Business
NK Cell Therapy Developer Quadruples San Diego Footprint
Artiva Biotherapeutics is quadrupling its footprint in San Diego with a 52,000 square-foot corporate HQ, R&D and manufacturing center opening next year.
August 12, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: August 4 – 10
Check out where the money went in the life sciences industry this week.
August 10, 2021
 · 
3 min read
 · 
Kate Goodwin
Andrey Zarur GreenLight CEO (GreenLight)
Deals
mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
August 10, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Aprea’s “Cancer Guardian” Protein Activator Drug Forced to Press Pause
Aprea faces another disappointment this week in the clinic. The FDA held up a yellow card, and the Boston-based biotech has placed a partial clinical hold on its myeloid malignancy program.
August 6, 2021
 · 
1 min read
 · 
Kate Goodwin
Deals
Money on the Move: July 28 – August 3
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
August 4, 2021
 · 
6 min read
 · 
Kate Goodwin
Courtesy Bodo Marks/Picture Alliance via Getty Ima
FDA
AstraZeneca’s FDA Approval Brings New Hope to the Lupus Community
Seventeen years after buying global rights, AstraZeneca is finally announcing a win for the lupus community with an FDA approval for Saphnelo.
August 2, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More